🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "major milestone" in the fight against superbug strains of the bacteria, according to scientists.

A Worldwide Health Concern

Gonorrhoea infections are increasing worldwide, with data suggesting more than 82 million new cases annually. Notably increased rates are reported in Africa and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary advancement in the context of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce therapeutic options at this time.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The World Health Organization has listed it as a "high-priority threat". Recent surveillance revealed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Gain Approval

Zoliflodacin, alternatively called Nuzolvence, was cleared by the American regulatory agency in mid-December for use against gonorrhoea. This STI can lead to major issues, including the inability to conceive. Scientists hope that specific application of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, also received approval in the same week. This drug, which is employed against urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

This new treatment was the result of a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This milestone signifies a huge turning point in the treatment of superbug gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Research Study Data and Global Access

According to findings detailed in a major medical journal, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This puts it on an comparable level with the current standard treatment, which involves a dual-drug approach. The study involved nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the ability to license and sell the drug in numerous regions with limited resources.

Clinicians treating patients have voiced hope. Having a one-pill regimen of this kind is described as a "critical tool" for gonorrhoea control. This is considered essential to reduce the burden of the disease for people and to stop the proliferation of untreatable gonorrhoea worldwide.